Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 5/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | MMP16 | P51512 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27538010 | 0.81 | SRC (0.45) | CXCL8PTGS2PTGS1L3MBTL1ALDH1A1 | |
| SCHEMBL360591 | 0.80 | CXCL8 (0.65) | CXCL8L3MBTL1ALDH1A1POLBLMNA | |
| SCHEMBL187738 | 0.80 | CXCL8 (0.56) | CXCL8ALDH1A1POLBLMNASMN1; SMN2 | |
| SCHEMBL11400557 | 0.80 | CXCL8 (0.52) | CXCL8PTGS2MMP1MMP2MMP9 | |
| SCHEMBL2204495 | 0.80 | PTGS2 (0.56) | CXCL8PTGS2MMP1MMP2MMP9 | |
| SCHEMBL22124874 | 0.79 | LMNA (0.47) | CXCL8L3MBTL1POLBLMNASMN1; SMN2 | |
| SCHEMBL22124875 | 0.79 | LMNA (0.47) | CXCL8L3MBTL1POLBLMNASMN1; SMN2 | |
| SCHEMBL15015554 | 0.77 | CXCL8 (0.54) | CXCL8PTGS2MMP1MMP2MMP9 | |
| SCHEMBL6121220 | 0.77 | CXCL8 (0.54) | CXCL8PTGS2MMP1MMP2MMP9 | |
| SCHEMBL11347940 | 0.77 | MDM4 (0.57) | CXCL8L3MBTL1ALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117956878-A | Perovskite layer manufacturing method, perovskite battery, battery assembly and photovoltaic system | 浙江爱旭太阳能科技有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117956878-A | Perovskite layer manufacturing method, perovskite battery, battery assembly and photovoltaic system | 浙江爱旭太阳能科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20080227790-A1 | Pyridazinone Derivatives and their Use as Pde4 Inhibitors | ALTANA PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| EP-1716123-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075437-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-4389415-A | ALPHA-METHYL-P-TYROSINE, HYDRAZINO PHENYLPROPIONIC ACID | MERCK & CO., INC. (US) | 1983-06-21 | — | — | US | disclosed |
| EP-0003353-A1 | A pharmaceutical composition for oral administration for treating hypertension | MERCK & CO. INC. (US) | 1979-08-08 | — | — | EP | disclosed |
| US-4163054-A | PHENYL HYDRAZINO SUBSTITUTED PROPIONIC ACID DECARBOXYLASE INHIBITOR AND GUANETHIDINE | MERCK & CO., INC. (US) | 1979-07-31 | — | — | US | disclosed |
| US-4086354-A | TRIMETHAPHAN CAMSYLATE OR CLONIDINE WITH A HYDRAZINO PHENYL SUBSTITUTED PROPIONIC ACID DECARBOXYLASE INHIBITOR | MERCK & CO., INC. (US) | 1978-04-25 | — | — | US | disclosed |
| US-4055645-A | HYDRALAZINE AND A HYDRAZINO PHENYL PROPIONIC ACID | MERCK & CO., INC. (US) | 1977-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227790-A1 | Pyridazinone Derivatives and their Use as Pde4 Inhibitors | PDE4A, PDE4B, PDE5A | CXCL8 4122/4885PTGS2 975/4885MMP1 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.